EYPT - Yutiq is due for Q1 2019 sales. However, it seems there is big opp for Dexycu in post cataract surgery inflammation due for Q2 2019 release. Don't really understand why it takes 1+ yr post FDA clearance to get going on sales to surgery centers given the high interest from clinicians in using Dexycu. Funding for building up sales team obtained from institutional investors earlier this year so there may not be financing risk for now. Lacking info on pricing.
Market Data 
Markets 
AI
